🇺🇸 FDA
Patent

US 9878006

Treatment of obesity and obesity related disorders by pharmalogical targeting of Kv1.3 potassium channels

granted A61KA61K38/00A61K38/16

Quick answer

US patent 9878006 (Treatment of obesity and obesity related disorders by pharmalogical targeting of Kv1.3 potassium channels) held by The Regents of the University of California expires Mon Jan 25 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Jan 30 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 25 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K38/00, A61K38/16, A61K38/17, A61K38/1767